Mostrando 10 resultados de: 36
Publisher
Journal of Nanobiotechnology(3)
Molecular Neurobiology(3)
Nanomaterials(3)
Frontiers in Aging Neuroscience(2)
Nanomedicine(2)
Área temáticas
Farmacología y terapéutica(26)
Enfermedades(25)
Medicina y salud(13)
Fisiología humana(7)
Ginecología, obstetricia, pediatría, geriatría(4)
Área de conocimiento
Farmacología(12)
Neurología(10)
Nanopartícula(8)
Biotecnología(7)
Ciencia de materiales(4)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(36)
ODS 9: Industria, innovación e infraestructura(29)
ODS 10: Reducción de las desigualdades(21)
ODS 12: Producción y consumo responsables(10)
ODS 2: Hambre cero(7)
Origen
scopus(36)
Human skin permeation studies with PPARγ agonist to improve its permeability and efficacy in inflammatory processes
ArticleAbstract: Rosacea is the most common inflammatory skin disease. It is characterized by erythema, inflammatoryPalabras claves:inflammation, limonene, Pioglitazone, PPAR-γ, ROSÁCEA, Skin permeationAutores:Calpena A.C., Espina M., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Rodríguez-Lagunas M.J., Silva-Abreu M.Fuentes:scopusEpigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
ArticleAbstract: Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated fPalabras claves:APPswe/PS1dE9 mice, Cognitive deficits, Epigallocatechin-3-gallate, hippocampus, obesity, unfolded protein responseAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusCorrection to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease (Molecular Neurobiology, (2018), 55, 9, (7327-7339), 10.1007/s12035-018-0868-4)
OtherAbstract: The original version of this article unfortunately contained mistake. The authors found that Fig. 4.Palabras claves:Autores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carrera M.V., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDevelopment of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization
ArticleAbstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase iPalabras claves:Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeationAutores:Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDiscovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice
ArticleAbstract: The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaPalabras claves:Autores:Andrisano V., Antoni Camins, Bartolini M., Brazzolotto X., Cieslikiewicz-Bouet M., Cisternas P., Colletier J.P., Coquelle N., De Simone A., Ettcheto M., Firuzi O., García M.L., Inestrosa N.C., Jean L., Muñoz-Torrero D., Nachon F., Oliva C.A., Perez B., Pons M., Renard P.Y., Rendina M., Ricchini M., Sanchez-Lopez E., Saso L., Silman I., Viayna E.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopus